Clinical Trials Browser

Adrenocortical Carcinoma × pembrolizumab × 90 days × Clear all

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Phase 2 Recruiting

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

NCT06066333 2026-02-03

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Phase 2 Recruiting

Adrenocortical Carcinoma

NCT05036434 2026-01-23

ACCOMPLISH

Phase 2 Active not recruiting

Adrenocortical Carcinoma